AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC

Shots: AstraZeneca has reported P-III (FLAURA2) trial findings on Tagrisso + Pt-based CT as a 1L treatment of pts with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC The P-III (FLAURA2) trial assessed Tagrisso (80mg, QD, PO) + pemetrexed + cisplatin/carboplatin (Q3W for 4 cycles) followed by Tagrisso + pemetrexed maintenance (Q3W) vs…

ByRidhi RastogiSeptember 8, 2025

NEWS

ELIAS Animal Health Reports Interim Study Data of ELIAS Cancer Immunotherapy (ECI) in Canine Osteosarcoma

Shots: ELIAS Animal Health has reported interim data from an ongoing study of ELIAS Cancer Immunotherapy (ECI) + CT in dog with osteosarcoma Trial assessed carboplatin (single dose) followed by ECI after 21 days (n=14) vs carboplatin alone (4 doses; n=14), showing 1yr. survival rates of 71% vs 21%; data was presented at ACVIM Forum…

ByRidhi RastogiJune 20, 2025

AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC

ELIAS Animal Health Reports Interim Study Data of ELIAS Cancer Immunotherapy (ECI) in Canine Osteosarcoma

Contact US

OUR INFORMATION

FOLLOW US